BROKENSHIRE COLLEGE

Madapo, Davao City

DRUG STUDY
Name of Client:_____________________________ Age:___ Sex:______ Date of Birth:__________ Marital Status:___________ Religion:____________
Chief Complaint/Reason for Admission:___________________________________________________________________________________________
Date and Time of Admission:_________________________________________ Accompanied by/Informant:___________________________________
Medical Diagnosis/Impression:________________________________________ Operation Perform (if any):____________________________________
GENERIC BRAND GENERAL MECHANISM ROUTE OF ADVERSE NURSING
INDICATIONS CONTRAINDICATIONS
NAME NAME CLASSIFICATION OF ACTION DOSAGE REACTIONS RESPONSIBILITY
Irinotecan Camptosar  Plant alkaloid Irinotecan Intravenous  First-line  CAMPTOSAR  Constipatio Assessment &
hydrochloride  Topoisomerase i prevents  2 mL-fill vial therapy in Injection is n Drug Effects
inhibitor relegation of the containing combination contraindicated in  Shortness  Lab tests:
DNA strand by 40 mg with 5- patients with a of breath Monitor WBC
binding to irinotecan fluorouracil known  Insomnia with
topoisomerase I- hydrochlori and hypersensitivity to (see sleep differential,
DNA complex, de leucovorin the drug or its problems) Hgb, and
and causes  5 mL-fill vial for excipients.  Cough platelet count
double-strand containing  patients with  Headache before each
DNA breakage 100 mg metastatic  Dehydratio dose; monitor
and cell death. irinotecan carcinoma of n closely
hydrochlori the colon or  Chills (see coagulation
de rectum. (1) flu-like parameters
 15 mL-fill  Patients with symptoms) especially with
vial metastatic  Skin rash concurrent use
containing carcinoma of (see skin of other drugs
300 mg the colon or reaction) which affect
irinotecan rectum  Flatulence these
hydrochlori whose (see parameters.
de disease abdominal  Lab tests:
 has recurred pain) Monitor fluid
or  Flushing of and electrolyte
progressed face during balance closely
following infusion during and after
initial  Mouth periods of
diarrhea.
fluorouracil- sores Monitor liver
based  Heartburn and renal
therapy.  Swelling of function tests
feet and and blood
ankles glucose
periodically.
 Monitor for
acute GI
distress,
especially early
diarrhea (within
24 h of
infusion), which
may be
preceded by
diaphoresis and
cramping, and
late diarrhea
(>24 h after
infusion).
Patient & Family
Education
 Learn about
common
adverse effects
and measures
to control or
minimize when
possible.
 Notify physician
immediately
when you
experience
diarrhea,
vomiting, and
S&S of
infection.
Diarrhea
requires
 prompt
treatment to
prevent serious
fluid and
electrolyte
imbalances.
 Do not breast
feed while
taking this drug.

Submitted by:____________________________________________________________________Clinical Instructor:_____________________________

Year and Section:_________________________________________________________________Date Submitted:_______________________________